J. Allen

发表

W. El-Deiry, J. Allen, J. Allen, 2012, Cancer biology & therapy.

A Bayesian machine learning approach for drug target identification using diverse data types

Olivier Elemento, Kaitlyn Gayvert, Paraskevi Giannakakou, 2019, Nature Communications.

Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9

W. El-Deiry, D. Dicker, N. Dolloff, 2012, Molecular Cancer Therapeutics.

Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.

Colin J. Daniel, E. Furth, R. Sears, 2011, Cancer research.

Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma

T. Cloughesy, L. Liau, P. Nghiemphu, 2020, bioRxiv.

Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.

W. El-Deiry, D. Dicker, V. Prabhu, 2015, Cancer research.

Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy

S. Khatua, T. MacDonald, S. McGovern, 2022, Neuro-oncology advances.

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway

W. El-Deiry, D. Dicker, Gen Sheng Wu, 2015, Molecular Cancer.

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

E. Messaris, W. El-Deiry, D. Dicker, 2013, Science Translational Medicine.

Therapeutic targeting of the p53 pathway in cancer stem cells

W. El-Deiry, Shengliang Zhang, Hairong Cheng, 2012, Expert opinion on therapeutic targets.

Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes

W. El-Deiry, D. Dicker, Wenge Wang, 2009, Cancer biology & therapy.

Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma.

T. Cloughesy, L. Liau, P. Nghiemphu, 2021, Radiotherapy and Oncology.

Novel antineoplastics targeting genetic changes in colorectal cancer.

W. El-Deiry, V. Prabhu, Jamal M. M. Joudeh, 2013, Advances in experimental medicine and biology.

Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases

W. El-Deiry, D. Dicker, J. Sheehan, 2011, Oncotarget.

Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma

S. Khatua, P. Robertson, S. Mueller, 2022, Neuro-oncology.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

M. Mehta, T. Niazi, W. Oster, 2019, Journal of neurosurgery. Pediatrics.

Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors

M. Rubin, O. Elemento, H. Beltran, 2021, Advanced materials.

Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein

W. El-Deiry, R. Muschel, Danmei Xu, 2015, Oncotarget.

Efficacy and Mechanistic Evaluation of Tic10, A Novel Antitumor Agent

J. Allen, J. Allen, 2012 .

Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation.

W. El-Deiry, Joshua E. Allen, J. Allen, 2011, Gastroenterology.

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

S. Khatua, M. Mehta, P. Wen, 2019, Journal of Neuro-Oncology.

Targeting TRAIL in the treatment of cancer: new developments

W. El-Deiry, B. Lim, N. Finnberg, 2015, Expert opinion on therapeutic targets.

Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma

M. Westhoff, T. Nguyen, G. Karpel-Massler, 2018, Clinical Cancer Research.

ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways

W. Oster, M. Duvic, T. Langridge, 2017, Oncotarget.

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

P. Wen, T. Batchelor, W. Oster, 2017, Oncotarget.

Extracellular Microenvironment in Patient-derived Hydrogel Organoids of Prostate Cancer Regulates Therapeutic Response

M. Rubin, O. Elemento, H. Beltran, 2020, medRxiv.

Targeting Oncoproteins for Molecular Cancer Therapy

W. El-Deiry, J. Allen, J. Allen, 2016, The Molecular Basis of Human Cancer.

The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype

W. El-Deiry, Xiuping Liu, Jingqing Yang, 2014, Cancer biology & therapy.

Discovery and clinical introduction of first-in-class imipridone ONC201

Neel S. Madhukar, Michael L. Wang, O. Elemento, 2016, Oncotarget.

Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor

P. Anderson, Joshua E. Allen, V. Prabhu, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.

W. El-Deiry, D. Dicker, Amriti R Lulla, 2016, Cancer research.

Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype

S. Mok, Suet-Ying Kwan, K. Lu, 2020, Cancers.

Leveraging external data in the design and analysis of clinical trials in neuro-oncology.

P. Wen, L. Trippa, M. Polley, 2021, The Lancet. Oncology.

Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver

W. El-Deiry, D. Dicker, Zhaohai Yang, 2015, Cancer biology & therapy.

Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors

W. El-Deiry, D. Dicker, Lanlan Zhou, 2012, Cell cycle.

ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro

K. Tucker, Yajie Yin, Yali Fan, 2020, Frontiers in Oncology.

Targeting PP2A inhibits the growth of triple-negative breast cancer cells

M. Chatterjee, Gen Sheng Wu, Z. Zhuang, 2020, Cell cycle.

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases

W. El-Deiry, D. Dicker, C. L. Kline, 2016, Science Signaling.

ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells

W. El-Deiry, D. Dicker, Joshua E. Allen, 2015, Cell cycle.

Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin

W. El-Deiry, J. Allen, 2013, Oncotarget.

Emerging molecular therapies for the treatment of acute lymphoblastic leukemia.

D. Claxton, Jamal M. M. Joudeh, J. Allen, 2013, Advances in experimental medicine and biology.

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors

Neel S. Madhukar, O. Elemento, U. McDermott, 2017, PloS one.

ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2

S. Sherman, Junsheng Ma, R. Bagheri-Yarmand, 2021, Molecular Cancer Therapeutics.

Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer

K. Tucker, L. West, Yajie Yin, 2021, Frontiers in Oncology.

ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer.

K. Tucker, Yajie Yin, Z. Fang, 2022, American journal of cancer research.

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells

I. Mills, R. Steele, K. Butterworth, 2021, Scientific Reports.

Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer

J. Parker, K. Tucker, D. Moore, 2020, Journal of Experimental & Clinical Cancer Research.

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

W. El-Deiry, L. Carlsen, Lanlan Zhou, 2020, Neoplasia.

Modulating the unfolded protein response: Impacts of radiation on the response of prostate cancer cells to ONC201

I. Mills, R. Steele, K. Butterworth, 2019, bioRxiv.

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

S. Libutti, Evita T. Sadimin, W. El-Deiry, 2019, Journal of Immunotherapy for Cancer.

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia

Neel S. Madhukar, Lauren E. Heese, O. Elemento, 2019, Leukemia.

Integrated stress response and immune cell infiltration in an ibrutinib‐refractory mantle cell lymphoma patient following ONC201 treatment

Michael L. Wang, Evita T. Sadimin, J. Schenkel, 2019, British journal of haematology.

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism

Jessica M. Rusert, Deric M. Park, Neel S. Madhukar, 2018, Clinical Cancer Research.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

U. McDermott, M. Garnett, C. Benes, 2018, Cell cycle.

Role of Dopamine Receptors in the Anticancer Activity of ONC201

W. El-Deiry, D. Dicker, Amriti R Lulla, 2017, Neoplasia.

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

C. Benes, W. El-Deiry, Amriti R Lulla, 2017, Cell cycle.

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma

M. Andreeff, R. Orlowski, Hua Wang, 2017, Neoplasia.

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors

R. DiPaola, W. El-Deiry, J. Bertino, 2017, Clinical Cancer Research.

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

Michael L. Wang, R. Davis, T. McDonnell, 2016, Science Signaling.

ONC201 Induces Apoptosis in Cutaneous T-Cell Lymphoma Cells through a Mechanism That Involves the Integrated Stress Response and Inactivation of Jak/Stat Signaling

M. Duvic, T. Langridge, X. Ni, 2015 .

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent

W. El-Deiry, Joshua E. Allen, R. Crowder, 2015, PloS one.

Abstract 2942: TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis

W. El-Deiry, D. Dicker, Amriti R Lulla, 2015 .

First-in-human dose escalation study of oral ONC201 in advanced solid tumors.

R. DiPaola, B. Haffty, M. Stein, 2015 .

Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.

Wafik S El-Deiry, W. El-Deiry, D. Dicker, 2015, Cancer research.

Genetic andPharmacological ScreensConverge in Identifying FLIP , BCL 2 , and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC 201 / TIC 10

D. Dicker, B. Lim, Joshua E. Allen, 2015 .

ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples

M. Andreeff, W. El-Deiry, T. Batchelor, 2014 .

Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins

W. El-Deiry, D. Dicker, Amriti R Lulla, 2014 .

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity

W. El-Deiry, D. Dicker, C. L. Kline, 2014, Oncotarget.

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

W. El-Deiry, D. Dicker, Charles D Smith, 2013, PloS one.

Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes

W. El-Deiry, D. Dicker, A. Kretz-Rommel, 2012, Molecular Cancer Therapeutics.

Therapeutic Discovery Targeting TRAILDeathReceptor 4 with Trivalent DR 4 Atrimer Complexes

D. Dicker, A. Kretz-Rommel, D. Oltean, 2012 .

Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer

W. El-Deiry, D. Dicker, Wenge Wang, 2011, Cancer biology & therapy.

Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents

Sharyn I. Katz, W. El-Deiry, D. Dicker, 2011, Cancer biology & therapy.

ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression

C. Wirtz, A. Peraud, M. Westhoff, 2021, Frontiers in Cell and Developmental Biology.

Translocation , TRAIL Gene Induction , and Potent Antitumor Effects Dual Inactivation of Akt and ERK by TIC 10 Signals Foxo 3 a Nuclear

E. Messaris, W. El-Deiry, D. Dicker, 2013 .

BIOM-22. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AS A MOLECULAR DETERMINANT OF GLIOBLASTOMA RESPONSE TO DOPAMINE RECEPTOR 2 (DRD2) INHIBITORS

F. Furnari, Jun Ma, Clark C. Chen, 2020, Neuro-Oncology.

From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer-selective Pathways

W. El-Deiry, Amriti R Lulla, Avital Lev, 2018, Early Drug Development.

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.

M. Mehta, P. Wen, T. Batchelor, 2019, Neuro-oncology.

EXTH-42. H3 K27M MUTANT GLIOMAS ARE SELECTIVELY KILLED BY ONC201, A SMALL MOLECULE INHIBITOR OF DOPAMINE RECEPTOR D2

P. Wen, H. Wakimoto, D. Cahill, 2017 .

Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022)

Ashutosh Kumar Singh, M. Rubin, O. Elemento, 2022, Advanced Materials.

First-in-human trial of ONC201 in patients with refractory solid tumors.

J. Bertino, B. Haffty, W. Oster, 2016 .

First-inHuman Clinical Trial of Oral ONC 201 in Patients with Refractory Solid Tumors

Oster, Sherri, R. DiPaola, 2019 .

Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.

M. Mehta, F. Lieberman, P. Wen, 2019, Journal of Clinical Oncology.

Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma

E. Shang, M. Westhoff, H. Akman, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Circulating Tumor Cells and Colorectal Cancer

W. El-Deiry, Wafik S. El-Deiry, Joshua E. Allen, 2010, Current colorectal cancer reports.

Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation

W. El-Deiry, D. Dicker, J. Liao, 2015, Cancer biology & therapy.

Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs

W. El-Deiry, D. Dicker, K. Peters, 2013, Oncotarget.

Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting.

D. Dicker, N. Dolloff, B. Faltas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 5248: Quantum dot multiplexing of prognostic marker and stem cell marker expression in colorectal cancer circulating tumor cells

W. El-Deiry, D. Dicker, K. Peters, 2011 .

Abstract 3818: CTC profiling: Integration of biomarker analysis with current Veridex CellSearch technology

W. El-Deiry, D. Dicker, K. Peters, 2011 .

A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer.

Xin Zhang, Jianqing Qiu, Yali Fan, 2021, Cancer biology & therapy.

Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors.

Susan M. Chang, M. Gilbert, P. Wen, 2022, Neuro-oncology.

Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor

D. Sibley, Y. Namkung, S. Laporte, 2021, Molecular Pharmacology.

ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies

M. Andreeff, W. El-Deiry, J. Ishizawa, 2014 .

ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition

R. Davis, T. McDonnell, M. Konopleva, 2014 .

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway

W. El-Deiry, D. Dicker, Gen Sheng Wu, 2015, Molecular Cancer.

Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia

R. Sinha, J. Pinto, I. Sinha, 2014, Cancer medicine.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer

W. El-Deiry, D. Dicker, R. Irby, 2013, PLoS ONE.

The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer

W. El-Deiry, D. Dicker, R. Irby, 2013, PloS one.

Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report

W. El-Deiry, D. Dicker, J. Sheehan, 2014, Oncology letters.

Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors.

F. Furnari, Jun Ma, Clark C. Chen, 2020, Neuro-oncology.

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Michael L. Wang, H. Lee, A. Zloza, 2017 .

A New Big-Data Paradigm for Target Identification and Drug Discovery

Neel Madhukar, Paraskevi Giannakakou, Kaitlyn Gayvert, 2017, bioRxiv.